← Back to Clinical Trials
Recruiting NCT06443268

NCT06443268 Cerebrovascular Disease: Quality of Life (CODE: QoL)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06443268
Status Recruiting
Phase
Sponsor University of Zurich
Condition Quality of Life
Study Type OBSERVATIONAL
Enrollment 680 participants
Start Date 2023-05-27
Primary Completion 2028-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
questionnaire, hair samples, blood samples, clinical exam

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 680 participants in total. It began in 2023-05-27 with a primary completion date of 2028-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers. The main question is: • to discover the factors associated with quality of life and stress in patient-caregiver dyads. Participants will be asked to fill out questionnaires and agree to provide a hair sample (in order to measure stress hormones in hair) and consent to use of their routine clinical and laboratory data. Researchers will compare a group of participants without stroke to establish a comparable baseline.

Eligibility Criteria

Control group: Inclusion criteria: * over 18 years old * No previous stroke OR previous stroke \>3 years ago * No significant disability (maximum mRS 1) * ambulatory patients at the University Hospital of Zurich (USZ), Dept. of Neurology * Patients' AND caregiver's ability to give informed consent * Patients' AND close relative's / caregiver's willingness to participate Exclusion criteria: • Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months Main Group: Inclusion criteria: * over 18 years old * Patients diagnosed with either transient ischemic attack, ischemic stroke or intracerebral hemorrhage and their caregivers * Caregiver of a patient as described above, age over 18 years * Hospitalized or ambulatory patients at the University Hospital of Zurich (USZ) included within 28 days from event. * Patients' AND caregiver's ability to give informed consent * Patients' AND caregiver's willingness to participate Exclusion criteria: • Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months

Contact & Investigator

Central Contact

Anton Schmick, MD

✉ anton.schmick@usz.ch

📞 +41442551111

Principal Investigator

Susanne Wegener, MD

PRINCIPAL INVESTIGATOR

University of Zurich

Frequently Asked Questions

Who can join the NCT06443268 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Quality of Life. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06443268 currently recruiting?

Yes, NCT06443268 is actively recruiting participants. Contact the research team at anton.schmick@usz.ch for enrollment information.

Where is the NCT06443268 trial being conducted?

This trial is being conducted at Zurich, Switzerland.

Who is sponsoring the NCT06443268 clinical trial?

NCT06443268 is sponsored by University of Zurich. The principal investigator is Susanne Wegener, MD at University of Zurich. The trial plans to enroll 680 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology